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Chlamydia trachomatis is an obligate, intracellular pathogen that causes the ocular 
infection known as trachoma and the Sexually Transmitted Infection (STI) known as 
chlamydia. C. trachomatis is the leading cause of preventable blindness, primarily in 
developing nations, and is also the most common cause of reportable, bacterial sexually 
transmitted infections both in the United States and world-wide [1]. C. trachomatis 
caused over 1.7 million reported cases in the United States in 2018, but including 
unreported cases, it is estimated that the total amount of infections reached over 2.86 
million [1]. Importantly, two-thirds of chlamydia cases are asymptomatic, making it 
difficult to reduce transmission and to prevent people from developing the sequalae 
associated with chlamydia. When chlamydial infections go untreated in women, the 
severity of the effects increase and can lead to serious diseases such as pelvic 
inflammatory disease, cervical cancer in conjunction with HPV infection, ectopic 
pregnancies, and infertility [1]. The large number of asymptomatic infections and overall 
known disease burden creates an urgent need for prevention methods such as 
vaccination. Development of vaccines requires a detailed understanding of how a 
pathogen causes disease [11]. However, Chlamydia’s pathogenic mechanisms are 
poorly understood, and genetic methods to discover these processes are limited and 
cumbersome [4]. 
C. trachomatis has a unique developmental cycle in which it converts between two 
structurally and functionally different forms (Fig 1)[3]. When an infection first begins, C. 
trachomatis is in an infectious form known as the Elementary Body (EB). The EB form 
utilizes a type 3 secretion system that allows for the bacterium to enter the epithelial cell 
leading to formation of a vacuole, called an inclusion, derived from the host’s cellular 
membrane. Within the inclusion, C. trachomatis then converts into the larger Reticulate 
Body (RB) form. The RB form is the replicative form that allows for bacterial growth and 
division. Within the inclusion, RBs will differentiate into the EB form and be released to 
infect more cells. If the bacteria are introduced to stressful conditions such as antibiotic 
treatment or host immune factors such as IFN-γ, they can enter a stage with low activity 
called persistence to ensure survival within the cell [12]. The methods and regulatory 
functions necessary to covert between forms and to allow for persistence to occur is not 
well known. In addition, growth in the host requires Chlamydia to manipulate the host 
cell to provide nutrients for the growing bacterial population while attempting to subvert 
the host’s immune response to avoid bacterial clearance [14]. As these collective steps 
are critical for pathogenesis, a molecular understanding of these processes could give 
rise to improved therapeutics or construction of live-attenuated vaccine strains. 
 
 
   
 
 
Figure 1. The Biphasic Developmental Cycle of Chlamydia trachomatis. C. 
trachomatis differentiates between two distinct forms. The Elementary Body (EB, red) 
constitutes the infectious form and allows for the initial infection of a cell and formation 
of the inclusion. Within the inclusion, the EB form coverts into the Reticulate Body (RB, 
green) which allows for replication within the inclusion. After replications occur, the RBs 
will convert back to EBs to exit the cell and continue infecting new cells and new hosts. 
 
A classical approach to delineate pathogenic mechanisms important for 
infections caused by C. trachomatis and other pathogens is to genetically modify the 
bacterium through gene inactivation. By removing the ability of a gene to function, we 
can discover whether the gene is essential for disease and/or its role in bacterial growth 
and virulence, and thus determine which genes would be good candidates for vaccine 
or antibiotic development. However, for C. trachomatis, only a limited and difficult to 
employ genetic tool kit exists, hindering our ability to study pathogenesis [4]. 
Thus, a goal of my project was to develop an improved mutagenesis system that 
creates gene-insertion mutants by utilizing a piece of DNA known as an intron. The 
current TargeTron mutagenesis system used in the field is based on the Ll.LtrB group II 
intron from Lactococcus lactis [5][6]. It was adapted by our lab for use in C. trachomatis 
[7].  Unfortunately, the mutation efficiency of the system is very low, making it difficult to 
create mutants in a timely manner. At its best, the Ll.LtrB system has an efficiency of 
10-6% when measured in Escherichia coli (Fisher lab, unpublished). My project focused 
on developing an alternative intron mutagenesis system for Chlamydia based on the 
EcI5 intron from E. coli (Fig 2)[2]. We hypothesized that this system would be an 
improvement in Chlamydia over the Ll.LtrB system because EcI5 functions best at 
37C, the optimal growth temperature for C. trachomatis, and because preliminary data 
from our lab has shown an increase in efficiency using the EcI5 intron in comparison to 
the Ll.LtrB system in E. coli. The inability to grow Chlamydia under axenic conditions 
makes it difficult to calculate efficiency, so we use E. coli as a surrogate system. My 
main aim was to test whether the EcI5 intron will continue to function better than the 
Ll.LtrB intron in E. coli after insertion of antibiotic resistance cassettes into the intron, 
and whether the EcI5 intron will be more efficient than the Ll.LtrB intron in C. 
trachomatis. Antibiotic selection is often essential for identifying mutant bacteria if the 
system is of low efficiency or the bacterium cannot be grown under axenic conditions, 
which hinders isolation of clones. A minor aim of my project was to determine the “rules” 




Figure 2. EcI5 Vector Map. The EcI5 intron is shown on a plasmid with intron 
expression controlled by the T7 promoter. The IEP region is located downstream of the 
intron. Resistance genes were placed at the MluI restriction enzyme site, which is where 
the IEP would be present in the wild type intron isolated from E. coli. 
 
 The EcI5 intron is able to find targeted sequences within a genome by utilizing 
the associated Intron Encoded Protein (IEP) in conjunction with sequence information in 
the 5’ region of the intron. It is the 5’ “targeting” sequence that researchers modify to 
target the intron to different genes. Once the EcI5 intron and its IEP have been 
transcribed and the IEP open reading frame has been translated, a lariat is formed that 
contains a protein part and an RNA part, known as a ribonucleoprotein [9]. The RNA 
portion is used to scan for targeted insertion sites within the genome via RNA-DNA 
base pairing. Once the binding site is found, the endonuclease activity of the IEP cuts 
both strands of the double stranded DNA target. Two more enzyme activities of the IEP, 
RNase and reverse transcriptase activities, allow for the insertion of the intron RNA into 
the cut area followed by conversion of the RNA to DNA. Once the intron is in the single 
stranded DNA form, the host cell’s replication system can replicate the intron DNA 
generating double stranded DNA containing the intron-disrupted gene (Fig 3). 
 
 
Figure 3. EcI5 mobility. EcI5 intron transcription is induced and EcI5 and intron 
encoded protein (IEP) transcripts are produced. The IEP transcript is then translated, 
and the IEP protein processes the EcI5 RNA to form a ribonucleoprotein lariat. The RNA 
portion has a 5’ located targeting sequence that scans the host chromosome for its 
unique insertion site. The IEP then provides endonuclease, reverse transcriptase, 













Sense orientation cuts the 
top strand, while antisense 
cuts the bottom.
IEP chews up the RNA, and the 
host's replication system replicates 
DNA from the other strand
III. Results 
We first confirmed that the wild-type EcI5 system performed at the high efficiencies 
reported by Zhuang et al. [2]. The intron was targeted to the lacZ gene (encodes β-
galactosidase) to allow for blue (wild type) -white (insertion mutant) colony screening on 
LB agar plates with the β-galactosidase colorimetric substrate X-gal. The 1806-1807 
lacZ insertion site was chosen for targeting, which should give rise to a sense intron 
insertion (http://www.targetrons.com/lacZ-EcI5-results.txt). Insertion efficiencies 
determined by counting white versus blue colonies were routinely above 70% (Table 1). 
Insertions were confirmed by performing PCR on randomly selected white colonies (Fig 
4).  
Next, we sought to determine the “rules” of the EcI5 mutagenesis system through 
the use of alternative intron designs and induction protocols. We selected the aadA 
(spectinomycin resistance), bla (ampicillin resistance), and cat (chloramphenicol 
resistance) genes for our study due to previous validation of these markers in the Ll.LtrB 
system with C. trachomatis or Chlamydia caviae [7][8][15].  All markers were either 
restriction digested or PCR-amplified from the pDFTT-Ll.LtrB vectors and ligated into 
the MluI digested lacZ-targeted EcI5 vector. Plasmids were selected that carried the 
genes in sense or anti-sense orientations to the intron and transformed into the E. coli 
BL21(de3) expression strain for intron mobility studies. The vector constructs are shown 
in Fig 5. 
 
 
Figure 4: PCR analysis of potential mutant colonies. PCR was performed using 
a lacZ primer and an intron primer to assess intron insertion. PCR products were 
resolved on 0.8% agarose gels, stained with ethidium bromide, and visualized using UV 
light. (A) A plate from the EcI5 positive control group was checked for white and blue 
colonies. White colonies have the intron insertion, while blue colonies have an 
uninterrupted lacZ gene. (B) One white colony from the aadA sense construct grown 
under the 3 hour + 1.0 mM IPTG condition was tested for EcI5 intron insertion. The 1.3 
kbp product supported that intron insertion occurred. (C) White colonies from the aadA 
RBS and ORF constructs grown under the 3 hour + 0.1mM IPTG were also tested for 
EcI5 intron insertion. The results came back positive with bands at 1.3 kbp, matching 
the expected size of the insertion product. Molecular weight markers are shown to the 










We found that the EcI5 vectors encoding the full aadA and bla antibiotic resistance 
genes (promoter, ribosomal binding site, open reading frame, and terminator sequence) 
within the intron at the MluI site produced lacZ-insertion efficiency rates that were under 
1% or were below our limit of detection of 0.01% (Table 1). These efficiencies were well 
below the non-antibiotic carrying intron, which inserted at an efficiency of ~70% (Table 
1). Note that the MluI site corresponds to where the EcI5 intron would have carried the 
Figure 5. EcI5 constructs. (A) Diagram of the wild type EcI5 intron with the IEP 
encoded within the intron. (B) The recombinant EcI5 mutants encoding an 
antibiotic resistance gene in place of the IEP region. The IEP is cis encoded 
downstream of the intron. (C) This figure illustrates the aadA RBS, aadA ORF, 
the aadA-3’, RAM, and RAMr constructs. The ORF construct is promoter-less 
and does not contain an RBS. The RBS construct is promoter-less but contains 
the RBS.  
intron-encoded protein (IEP, Fig 2). For mutagenesis purposes, the IEP is encoded 
downstream from the intron. Note that the IEP would not possess a promoter sequence 
when encoded within the EcI5 as expression would rely on the intron promoter. For the 
mutagenesis system, the intron promoter is lost upon gene intron insertion into the 
chromosome and any cargo within the intron would need its own promoter for 
expression.  
Since insertion efficiencies were low with the resistance cassette constructs, we next 
varied the incubation intervals and inducer concentrations to determine if growth and 
induction conditions affected insertion efficiency. In one trial, we produced one mutant 
colony from the aadA sense construct after a 3-hour incubation condition with 1.0 mM 
IPTG (inducer), suggesting that the sense orientation might be preferred (Table 1, Fig 
4). This result also supports that the efficiency rates of the EcI5 mutagenesis system 
could represent a large improvement over the previous Ll.LtrB system, which had a 
maximum insertion efficiency of 10-6%. We also tested a smaller antibiotic cassette, the 
cat gene, to see if cargo size (975 bp cat, 1.2 kbp bla, 1.3 kbp aadA) was negatively 
impacting mobility. This construct did not make a difference in insertion efficiency as 
rates were still less than 2.9-2%. During these experiments, we observed that growth of 
the recombinant E. coli strains was reduced with high levels of IPTG (1.0 mM IPTG) and 
that all of the strains tested seemed to grow best with the 3-hour incubation time, so we 
made the 3 hour incubation standard for the rest of the trials using the modified 
resistance cassettes.  
 
Table 1. Insertion efficiency assay results for aadA (sense and antisense), bla 
(sense), and cat (sense and antisense) vectors
 
As the IEP would not possess an internal promoter in the wild type intron, we 
hypothesized that the resistance gene promoters might be interfering with intron 
mobility. To test our hypothesis, we developed new constructs lacking the promoter 
(aadA RBS), both the promoter and RBS (aadA ORF), or the 3’ region (aadA-3, data not 
shown) of the antibiotic resistance gene. We used the sense orientation of the aadA 
resistance gene because we had seen one positive mutant colony in our previous 
results (Fig 4). All constructs were grown for 3 hours with 0.1 mM IPTG or 1.0 mM 
IPTG. The ORF and RBS constructs produced mutant colonies (Fig 4), and the insertion 
efficiency levels began to approach the efficiency levels of the wild type EcI5 intron 
lacking a resistance gene insert (Fig 6). The aadA-3 construct, which still encoded the 
promoter and RBS, yielded no white colonies (efficiency <0.24%, personal 
communication from Derek Fisher). These results suggested that there might be 
promoter competition between the intron promoter and the antibiotic resistance gene 
promoter leading to low expression of the full-length intron. 
 
 
Figure 6. Insertion efficiency assays of aadA RBS (sense and antisense) and 
aadA ORF (sense and antisense). (A) White colonies were seen for each construct 
under 3 hours + 0.1mM IPTG. The number of white colonies per total colonies was used 
to calculate insertion efficiency.  (B) White colonies were also observed for each 
construct under 3 hours + 1.0 mM IPTG.  
 
To attempt to block promoter competition, we decided to insert a Retrotransposable 
Activated Marker (RAM) within the promoter region. A RAM cassette is a 400-base pair, 
type I intron that has the ability to self-splice out of a region of RNA upon transcription 
[10]. In our system, we placed the RAM cassette between the -35 and -10 regions of the 
bla antibiotic resistance gene promoter. The bla gene was selected rather than the 
aadA gene as the bla promoter is well characterized. We hypothesized that the RAM 
intron would cause the promoter region to be unrecognizable within the DNA allowing 
for unfettered transcription from the intron promoter. After transcription, the RAM should 
self-splice reconstituting function of the antibiotic resistance gene. We also wanted to 
determine if the orientation of the antibiotic resistance gene in reference to the RAM 
cassette played a role in insertion efficiency. We utilized the bla antibiotic resistance 
gene in the antisense orientation with the RAM cassette inserted into its respective 
promoter region. Neither use of the RAM cassette or RAM orientation rescued intron 
insertion efficiency (Tables 2 and 3). 
 
Table 2. Insertion efficiency assay results for RAM vector. 
 





Current methods for mutagenesis in C. trachomatis include our intron approach, 
transposon mutagenesis, allelic exchange, chemical mutagenesis, and TILLING 
[7][13] [16][17][18]. While useful, all of these approaches have limitations, and none 
have been uniformly adopted across the field. In this study, our goal was to create a 
new intron mutagenesis system for Chlamydia based on the EcI5 intron from E. coli. 
Although we were not able to create a system that was functional and provided a 
means of selection within Chlamydia, we were able to discover rules associated with 
the EcI5 system. 
The study began by developing the bla (sense), aadA (sense & antisense), and 
cat (sense & antisense) vectors by utilizing restriction enzyme digestion at the MluI 
site on the plasmid. We then tested these vectors for intron mobility at various 
induction periods and concentrations of the inducing agent, IPTG, within E. coli. We 
found that the constructs with antibiotic resistance markers had insertion efficiency 
rates that were significantly lower than the construct with the wild type intron, as we 
were unable to detect mutants with the exception of one trial. This one success in E. 
coli was still a drastic improvement over the Ll.LtrB system. The results also show 
an ~106-fold improvement in insertion efficiency with the marker-less EcI5 over the 
Ll.LtrB intron in E. coli. Upon the addition of resistance genes, the insertion 
efficiency was significantly reduced, regardless of orientation. This suggests that 
there could be competition between the resistance gene promoter and the intron 
promoter. Alternatively, placing genes within the IEP region of the intron might cause 
issues with lariat folding, also resulting in decreased efficiency.  
In order to determine the cause of the decrease in efficiency, we created 
constructs that removed either the promoter regions, ribosomal binding site, or both 
areas within the antibiotic resistance gene in the intron. Like the previous constructs, 
these were also made by utilizing restriction enzyme digestion at the MluI site on the 
plasmid. Vectors were then tested at the two testing conditions that worked best in 
the original experiments, 3hr + 0.1mM IPTG & 3hr + 1.0 mM IPTG. We found that 
the promoter-less construct (aadA RBS) and a construct without a promoter or RBS 
(aadA ORF) had efficiency rates close to the wild type levels suggesting that a 
smaller insert and/or lack of a promoter within the IEP region was preferred. We also 
assessed the impact on mobility of sequences 3’ to the antibiotic gene ORF. 
Removal of the 3’ sequence did not result in improved efficiency. Note that the 3’ 
constructs still encoded the antibiotic gene promoter and RBS. Overall, the results 
suggest that including the promoter region significantly reduces insertion efficiency. 
Although the EcI5 intron system appears more efficient than Ll.LtrB with the aadA 
ORF and aadA RBS constructs, lacking a promoter for the antibiotic resistance gene 
would cause problems in the future when attempting to select for mutants in C. 
trachomatis. 
Finally, we attempted to transiently inactivate the promoter region of the antibiotic 
resistance gene until after transcription of the intron and IEP has occurred. To do 
this, we utilized a Retrotransposable Activated Marker that was inserted to interrupt 
the promoter region of the resistance gene, making it unrecognizable to the RNA 
polymerase during transcription from the intron-carrying plasmid. Following 
transcription, the RAM cassette should self-splice out of the RNA and allow for the 
promoter to be recognizable again after the intron inserts into the targeted gene, 
enabling the selection of mutants. However, our results showed that we were unable 
to detect any mutants with this construct, suggesting that either the promoter being 
present following transcription still posed a problem or that the RAM cassette was 
not functioning as predicted. 
Based on the results of this study, we can conclude that the EcI5 group IIB intron 
mutagenesis system does provide a higher insertion efficiency than the previously 
used Ll.LtrB L. lactis system when used in E. coli. However, insertion of a second 
promoter within the intron drastically decreases insertion efficiency. It should be 
noted that the Ll.LtrB intron used for comparison to the EcI5 intron carries a kan-
RAM cassette, which could impact insertion efficieny. Future work should focus on 
further developing and improving upon the RAM system to resolve the promoter 
competition issue. We should also utilize the ORF construct previously made to 
create mutations by placing it under the control of the targeted gene’s promoter to 
transcribe and translate the selection marker within the intron, thus giving us 







Strains and growth conditions: 
E. coli NEB10 (New England BioLabs) was used for cloning steps and was 
routinely cultured at 37°C in LB broth or on LB agar plates in the presence of 20 
µg/mL chloramphenicol when carrying vectors (Fig 5).  Vectors were transformed into 
the E. coli BL21(de3) expression strain and grown as described in the results section for 
mobility experiments. LB agar plates containing 40 µg/mL X-gal and 20 
µg/mL chloramphenicol were used for blue-white screening. Plates were incubated at 
37°C for 24 hours prior to blue-white assessment.  
Vector Construction: 
The EcI5 Group IIB intron from E. coli is able to splice and insert itself into 
specific, targeted locations within bacterial chromosome with the help of an Intron-
Encoded Protein (Fig 3). Our EcI5 intron was targeted to the lacZ gene (encoding beta-
galactosidase) using the gBlock approach described in http://www.targetrons.com/lacZ-
EcI5-results.txt. Targeting to this gene enabled a screening method to help identify the 
desired mutants. The lacZ encoded β-galactosidase is utilized to break down lactose, 
and in our case, the colorimetric substance X-gal, which leads to the production of a 
blue color within the colonies. Colonies that grew blue on the plate had a normal lacZ 
gene and β-galactosidase activity and could breakdown the X-gal within the media. 
Colonies that grew white had the EcI5 intron interrupting the lacZ gene and thus could 
not utilize the X-gal. White colonies were PCR verified to ensure that the intron had 
inserted into the correct location. Primers for the lacZ-EcI5 PCR are listed in Table 4. 
Thermo Scientific PCR Master Mix was used for colony PCR reactions and the primers 
were used at 0.5 µM (primers were ordered from Integrated DNA Technologies). 
Within the intron, we placed various antibiotic resistance markers to allow for 
selection of mutants. Clones were designed using CloneManager software. Cloning 
PCR reactions used Phusion polymerase (Thermo Scientific). Resistance markers were 
chosen based on their success within the L. lactis intron [7][8][15]. Genes or PCR 
products for the bla (sense), aadA (sense & antisense), cat (sense & 
antisense), aadA RBS (sense and antisense), aadA ORF (sense and antisense), and 
aadA-3 were digested with MluI and ligated into similarly digested plasmids. Ligation 
products were transformed into E. coli NEB10. To construct the bla RAM vector, the 
RAM intron was PCR amplified from pACD4-K and the bla vector was PCR amplified 
using primers with 20 bp overlaps with the RAM cassette. Both PCR products were then 
linked using the NEB HiFi DNA assembly as directed by the manufacturer (New 
England BioLabs). E. coli transformants were screened by PCR for insert presence and 
orientation relative to the intron (primers in Table 4) and plasmids were then isolated for 
Sanger DNA sequencing (performed by PSOMAGEN). Sequence-verified vectors were 







    
Table 4. lacZ detection and gene cloning primers 






























































































The recombinant BL21(de3) strains were grown overnight in LB with 20 
µg/mL chloramphenicol at 37°C. 50 µL of bacteria were then subcultured into 5 ml LB 
with 20 µg/mL chloramphenicol and grown until an optical density at 600nm of 0.2-0.3 
was reached. 200 µL of bacteria were then subcultured in 5 mL LB with 20 
µg/mL chloramphenicol and the test amount of IPTG. The subculture was grown for 
different time periods prior to dilution in PBS to ~1,000 CFU/ml and plating of 100 µl on 
LB agar plates containing 40 µg/mL X-gal and 20 µg/mL chloramphenicol. OD 600nm 
readings were used to estimate bacterial numbers prior to dilution (OD 600nm 1 = 5x108 
CFU/ml). Plates were incubated at 37°C for 24 hours prior to analysis. Colonies 
containing mutant bacteria would remain white while nonmutants would have no 
interruption of the lacZ gene and would be able to break down the X-gal, giving rise to 
blue colonies. For any white colonies, orientation PCR was performed using the forward 
primer, LacZ F2, and the reverse primer, UnivEcIR, to confirm the presence of the EcI5 
intron. The PCR samples were run on a 0.8% agarose gel for 30 minutes, stained with 
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